Fig. 6: Co-treatment of lenvatinib and AXL exerts therapeutic effects in preclinical HCC mouse model. | Cell Death & Disease

Fig. 6: Co-treatment of lenvatinib and AXL exerts therapeutic effects in preclinical HCC mouse model.

From: Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer

Fig. 6

A Schematic diagram illustrating the treatment scheme of either BGB324 or lenvatinib alone, or in combination with lenvatinib and BGB324 in lenvatinib non-responsive spontaneous liver tumors established by hydrodynamic tail vein injection of oncogenic plasmids. B Representative images of livers resected from mice receiving either BGB324 or lenvatinib alone, or the combination treatment. Scale bar = 1 cm. C Liver to body weight ratio of mice after treatment (n = 8 per group). Data representative of one experiment. D Representative H&E and IHC images showing p-PDPK1, HMGB1, calreticulin, CD8α, and CD103 expression in the tumor sections after single or combination treatment. Scale bar = 100 µm and 50 µm (inset). Red arrows indicating positive signals of CD8α and CD103. E Bar charts showing the quantification of p-PDPK1, HMGB1, calreticulin staining intensities, and CD8α+ and CD103+ cells in three independent fields. **p < 0.01 on a Cox–Mantel log-rank test in the survival curve. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s. not significant on one-way ANOVA with Bonferroni’s multiple comparisons test.

Back to article page